Skip to main content Skip to section navigation Skip to footer

chevron_leftBack to Evommune.com

Check Out the EADV Webinar of Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria.

Click Here

About Us
Our Science
Our Pipeline
Join Us
- Our Culture
- Job Openings
Investors & Media

Select Page

Overview
Company Info
News & Events
Stock Data
Financial & Filings
- Financial Results
- SEC Filings
Corporate Governance
Back to Evommune.com

Financial Results

Overview

Overview
Company Info
News & Events
Stock Data
Financial & Filings
- Financial Results
- SEC Filings
Corporate Governance

Financial & Filings
Financial Results
SEC Filings

2025

FY 2025

Fiscal Year Ended Dec 31, 2025

Earnings ReleaseHTML

10-KHTML XBRL Zip

Q3 2025

Quarter Ended Sep 30, 2025

Earnings ReleaseHTML

10-QHTML XBRL Zip

Company Profile
Contacts
RSS News Feed
Sitemap
Accessibility Statement

About Us

Overview
Leadership
Collaborating
Contact

Our Science

Approach
Disease Focus
Publications & Posters

Our Pipeline

Development Pipeline
MRGPRX2 Antagonist
IL-18bp Fusion Protein
Clinical Trials

Join Us

Our Culture
Job Openings

Investors & Media

Overview
Company Info
News & Events
Stock Data
Financial & Filings
Corporate Governance

© 2026 Evommune, Inc.

Privacy Policy
Terms of Use

Website by 22 Fillmore